Centene Corporation
CNC
$69.41
+4.50%
Centene Corporation is a managed care organization focused on government-sponsored healthcare programs, operating Medicaid, Medicare, and individual exchange plans, and serving roughly 20 million medical members as of December 2025, with Medicaid representing about 64% of membership, the individual exchanges about 28%, and Medicare about 5%, plus a Medicare Part D pharmaceutical business. As one of the largest pure-play government health insurers in the United States, Centene occupies a distinct niche relative to diversified peers like UnitedHealth and CVS, deriving the bulk of its revenue from state Medicaid contracts and ACA marketplace subsidies, which makes it highly sensitive to policy, enrollment, and acuity trends. The current investor narrative has swung sharply from distress to recovery: after a brutal 2025 marked by a Q3 net loss of $6.63 billion and a Q4 loss of $1.1 billion tied to elevated medical costs, the stock has staged a dramatic rebound, with headlines in 2026 focused on membership declines in ACA plans, cost-cutting through voluntary staff buyouts, and a larger-than-expected 2027 Medicare Advantage payment rate increase from CMS that lifted sentiment across managed care. The debate now centers on whether Centene's margin recovery is durable and whether Medicaid redetermination and exchange attrition will be offset by pricing discipline and operating leverage.…
CNC
Centene Corporation
$69.41
Related headlines
Investment Opinion: Should I buy CNC Today?
We assign a Hold rating on Centene, balancing the impressive Q1 2026 margin recovery and deep value valuation against persistent membership headwinds and execution risks. The analyst consensus is 'buy' with an average target of $71.78, implying 8.1% upside, but the modest upside and wide target range ($56-$85) suggest limited near-term conviction. The core thesis is that Centene is a show-me story: the market needs evidence that the margin recovery is sustainable before awarding a higher multiple.
The supporting evidence for a Hold is mixed. On the positive side, Q1 2026 revenue grew 7.13% year-over-year to $49.94 billion, gross margin rebounded to 21.9%, and free cash flow was a robust $3.4 billion in the quarter. The stock trades at a price-to-sales ratio of 0.10 and price-to-book of 1.01, near historic lows, and the forward PE of 12.50 is undemanding. However, trailing profitability remains negative with a net margin of -3.43%, and the company is losing ACA members, which forced cost-cutting through buyouts. The debt-to-equity of 0.94 and cash flow to debt of 0.22 are manageable but not strong.
The biggest risks that could invalidate the thesis are a reacceleration of medical cost inflation, further ACA membership attrition, and unfavorable Medicaid rate updates. The rating would upgrade to Buy if gross margins hold above 20% for two consecutive quarters and membership stabilizes, or if the forward PE compresses below 10x. It would downgrade to Sell if revenue growth turns negative or if margins fall back below 15%. Relative to its own history, the stock is deeply undervalued on sales and book value, but the discount may be justified by structural pressures. We view the stock as fairly valued at current levels, with a slight edge to the upside if execution improves.
Sign up to view all
CNC 12-Month Price Forecast
Centene presents a balanced risk/reward profile. The company has demonstrated a sharp margin recovery in Q1 2026, with gross margin returning to 21.9% and net income of $1.54 billion, yet trailing profitability remains negative and membership headwinds persist. The valuation is undemanding at 0.10x sales and 12.5x forward earnings, but the market is clearly pricing in skepticism about the durability of the recovery. Analyst sentiment is moderately bullish with a 'buy' consensus and $71.78 average target, but the wide range ($56-$85) reflects uncertainty. We would upgrade to bullish if gross margins hold above 20% for two consecutive quarters and ACA membership stabilizes; we would downgrade to bearish if margins fall below 18% or if revenue growth turns negative. Given the current data, a neutral stance with a medium confidence is appropriate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $71.78 and implied upside of +3.4% versus the current price.
Average Target
$71.78
0 analysts
Implied Upside
+3.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$56 - $85
Analyst target range
Centene is covered by 18 analysts with a consensus recommendation of "buy" and a recommendation mean of 2.33 (where lower numbers indicate stronger buys). The average target price is $71.78, which implies approximately 8.1% upside from the current price of $66.42. The consensus leans moderately bullish, supported by the estimated forward EPS average of $9.06 and estimated revenue average of $216.89 billion, though the relatively modest upside to the average target suggests analysts see the stock as approaching fair value after its massive run.
The target price range spans from a low of $56.00 to a high of $85.00, a spread of $29.00 or roughly 52% of the low target, indicating meaningful disagreement among analysts about the company's trajectory. The high target of $85.00 implies about 28% upside and would likely require multiple expansion on top of the earnings recovery, potentially driven by successful cost-cutting, favorable Medicaid rate updates, or a larger-than-expected Medicare Advantage payment increase. The low target of $56.00 implies about 15.7% downside and likely prices in continued membership attrition in ACA plans, Medicaid rate pressure, or margin compression from elevated medical costs. Institutional ratings show a mix of Overweight/Buy ratings from Cantor Fitzgerald, B of A Securities, Truist Securities, and Barclays, balanced against Neutral/Equal Weight/Sector Perform ratings from Wells Fargo, RBC Capital, JP Morgan, Mizuho, Morgan Stanley, and UBS, with no recent upgrades or downgrades, suggesting analysts are in a holding pattern awaiting clearer evidence on margin sustainability.
Drowning in data?
Find the real signal!
Bulls vs Bears: CNC Investment Factors
The bull case for Centene rests on a powerful margin recovery, deep value valuation, and strong cash flow, while the bear case highlights membership attrition, negative trailing profitability, and the risk that the low valuation reflects structural challenges. Currently, the bull evidence appears stronger given the Q1 2026 earnings turnaround and analyst consensus, but the bear arguments are not fully resolved. The single most important tension is whether the Q1 2026 margin recovery is sustainable or merely a temporary rebound from an unusually bad 2025. If margins hold above 20% and membership stabilizes, the stock could re-rate significantly; if not, the low valuation may persist or worsen.
Bullish
- Dramatic margin recovery in Q1 2026: Q1 2026 gross margin rebounded to 21.9% from 15.2% in Q4 2025 and 16.4% in Q3 2025, driving net income of $1.54 billion and operating margin of 3.73%. This sharp sequential improvement suggests the worst of the medical cost pressure is behind the company.
- Extremely low valuation multiples: The stock trades at a price-to-sales ratio of 0.10 and price-to-book of 1.01, near historic lows. The forward PE of 12.50 is well below the broader market and implies the market is pricing in a moderate earnings recovery despite the recent operational turnaround.
- Strong free cash flow generation: Trailing twelve-month free cash flow is $6.35 billion, and Q1 2026 alone generated $3.4 billion in free cash flow on $3.6 billion of operating cash flow. This robust cash generation provides ample liquidity and supports the company's ability to invest in growth or reduce debt.
- Analyst consensus sees upside: 18 analysts rate the stock a 'buy' with an average target price of $71.78, implying 8.1% upside from the current $66.42. The high target of $85.00 suggests 28% upside if margin recovery accelerates and membership trends stabilize.
Bearish
- Recent membership declines pressure revenue: Centene is experiencing a significant loss in Affordable Care Act membership, which represents about 28% of total membership. This has forced cost-cutting through voluntary staff buyouts, signaling near-term revenue pressure and potential disruption to operations.
- Trailing profitability remains deeply negative: Despite the Q1 2026 recovery, the trailing twelve-month net margin is -3.43% and operating margin is -3.91%, reflecting the massive $6.63 billion Q3 2025 loss and $1.1 billion Q4 2025 loss. The company's ROE is -33.44%, indicating significant value destruction over the past year.
- Valuation may be a value trap: The PS ratio has collapsed from 1.29 in Q4 2022 to 0.10 today, a 92% decline, and the price-to-book is just above 1. While this suggests deep value, it could also reflect structural pressures on Medicaid and exchange margins that may persist, limiting multiple expansion.
- High leverage and modest cash flow to debt: Debt-to-equity stands at 0.94, and the cash flow to debt ratio is only 0.22, indicating that despite strong absolute free cash flow, the debt burden remains significant relative to cash generation. This limits financial flexibility if margins deteriorate again.
CNC Technical Analysis
Centene is in a powerful, sustained uptrend that has recovered dramatically from a deep drawdown. The stock is up 94.89% over the past year and 92.80% over six months, with a current price of $66.42 sitting at approximately 92% of its 52-week range (52-week low of $31.63, high of $69.36). That positioning near the top of the annual range signals strong momentum but also raises the risk of overextension, especially given the stock's max drawdown of -32.73% earlier in the cycle, which underscores how violently this name can reverse. The 1-year relative strength versus SPY of +78.67 percentage points confirms Centene has been a decisive market outperformer over the trailing twelve months.
Short-term momentum, however, has flattened and diverges from the powerful longer-term trend. The stock is down 0.97% over the past month and up only 1.89% over three months, a stark deceleration from the 92.80% six-month gain, while the 1-month relative strength versus SPY is a modest +0.09 percentage points and the 3-month relative strength is actually negative at -1.15 percentage points. This divergence between a soaring 1-year trend and a stalling 1-month/3-month trend suggests the recovery rally has entered a consolidation phase, with the market digesting gains rather than pressing higher. The most recent session showed a +1.56% bounce on volume of about 3.63 million shares, and the short ratio of 3.26 indicates short sellers are not aggressively positioned against the name, reducing the likelihood of a violent short squeeze but also removing a potential upside catalyst.
Key technical levels are well defined by the 52-week range. Resistance sits at the 52-week high of $69.36, roughly 4.4% above the current $66.42 price; a decisive breakout above that level would confirm the uptrend's continuation and likely draw momentum buyers. Support is anchored at the 52-week low of $31.63, though a more relevant near-term support zone would be the $60-$62 area where the stock consolidated in July and August 2026; a breakdown below $60 would signal that the recovery is losing steam. With a beta of 1.106, Centene is about 10.6% more volatile than the broader market, meaning position sizing should account for slightly amplified drawdown risk relative to SPY, particularly given the stock's history of sharp -30%+ corrections.
Beta
1.11
1.11x market volatility
Max Drawdown
-32.7%
Largest decline past year
52-Week Range
$32-$70
Price range past year
Annual Return
+108.7%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | +2.9% | -2.0% |
| 3m | +13.1% | +1.4% |
| 6m | +92.0% | +15.0% |
| 1y | +108.7% | +15.7% |
| ytd | +66.1% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Centene's revenue trajectory remains solidly growing, with Q1 2026 revenue of $49.94 billion representing 7.13% year-over-year growth from Q1 2025's $46.62 billion. The multi-quarter trend shows steady top-line expansion, with revenue rising from $48.74 billion in Q2 2025 to $49.69 billion in Q3 2025, $49.73 billion in Q4 2025, and $49.94 billion in Q1 2026, indicating consistent sequential growth even through the period of margin distress. Segment data shows the Medicaid segment is the dominant driver at $39.21 billion, dwarfing the Commercial segment at $9.56 billion and Other at $1.18 billion, meaning Centene's growth is overwhelmingly levered to Medicaid enrollment and rate dynamics. The key question for the investment case is whether this revenue growth can be converted into sustainable profitability, given that the top line has grown even as the company swung to significant losses in 2025.
Profitability has been highly volatile but is showing a sharp recovery. Q1 2026 delivered net income of $1.54 billion with a 21.9% gross margin, a dramatic turnaround from the Q3 2025 net loss of $6.63 billion (gross margin 16.4%) and Q4 2025 net loss of $1.1 billion (gross margin 15.2%). The Q1 2026 net income ratio of 3.09% and operating margin of 3.73% compare favorably to the negative operating margins of -14.0% in Q3 2025 and -3.5% in Q4 2025, suggesting the worst of the medical cost pressure may be behind the company. However, the trailing twelve-month picture remains negative, with a net margin of -3.43% and operating margin of -3.91%, reflecting the drag from the 2025 losses. For a managed care organization, gross margins in the low-to-mid 20% range are more typical of a healthy environment, so the Q1 2026 gross margin of 21.9% represents a return toward normalized levels after the 2025 compression.
The balance sheet and cash flow profile are adequate but not without risk. Centene carries a debt-to-equity ratio of 0.94 and a current ratio of 1.68, indicating reasonable liquidity but meaningful leverage. Free cash flow on a trailing twelve-month basis is a robust $6.35 billion, and Q1 2026 alone generated $3.4 billion in free cash flow on $3.6 billion of operating cash flow, demonstrating strong cash generation when operations normalize. The company holds $20.59 billion in cash as of Q1 2026, up from $17.89 billion at year-end 2025, providing a substantial liquidity buffer. However, ROE is deeply negative at -33.44% on a trailing basis due to the 2025 losses, and the cash flow to debt ratio of 0.22 from the most recent historical ratios data suggests that while cash generation is improving, it remains modest relative to the debt load.
Quarterly Revenue
$49.9B
2026-03
Revenue YoY Growth
+7.1%
YoY Comparison
Gross Margin
21.9%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Because Centene's trailing net income is negative (EPS of -$0.33, trailing PE of -3.02), the PE ratio is not meaningful as a primary valuation metric, and the EV/EBITDA of -4.10 is similarly distorted by negative trailing EBITDA. The most appropriate metric is the price-to-sales ratio of 0.10, which is exceptionally low, or the forward PE of 12.50, which reflects the market's expectation of a return to profitability. The enormous gap between the negative trailing PE and the positive forward PE of 12.50 implies the market is pricing in a sharp earnings recovery, consistent with the Q1 2026 net income of $1.54 billion and analyst EPS estimates averaging $9.06 for the forward period.
On a peer comparison basis, Centene's PS ratio of 0.10 is remarkably low for a company with nearly $200 billion in annualized revenue, and its forward PE of 12.50 is well below the broader market and likely below the managed care sector average, though specific industry average data is not available in the provided dataset. The price-to-book ratio of 1.01 means the stock trades essentially at book value, which for a company with $20.59 billion in cash and a recovering earnings profile could represent a value opportunity. The EV/Sales of 0.12 further underscores how cheaply the market is valuing Centene's revenue stream, though this discount likely reflects the market's concern about Medicaid rate pressure, ACA membership attrition, and the sustainability of margin recovery.
Historically, Centene's valuation has compressed dramatically. The PS ratio stood at 1.29 in Q4 2022, 1.00 in Q4 2023, and has fallen to 0.10 currently, representing a roughly 92% decline in the sales multiple over that period. Similarly, the price-to-book ratio has fallen from 1.91 in Q4 2022 to 1.01 today. This places the stock near the bottom of its own historical valuation band, which could signal either a deep value opportunity if earnings normalize as the forward PE suggests, or a value trap if structural pressures on Medicaid and exchange margins persist. The forward PE of 12.50 versus the historical PE range of 7-27x (excluding negative-earnings quarters) suggests the market is pricing in a moderate recovery but not a full return to prior profitability levels.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Centene faces significant financial and operational risks. The company's debt-to-equity ratio of 0.94 and cash flow to debt ratio of 0.22 indicate meaningful leverage relative to cash generation, despite $20.59 billion in cash. The trailing twelve-month net margin is -3.43% and ROE is -33.44%, reflecting the impact of $7.73 billion in combined losses in Q3 and Q4 2025. Revenue is heavily concentrated in Medicaid (64% of membership) and the individual exchanges (28%), making the company vulnerable to policy changes, enrollment shifts, and acuity trends. The recent ACA membership slump, which forced staff buyouts, highlights the operational risk of fixed costs not adjusting quickly enough to revenue declines.
Market and competitive risks are substantial. The stock trades at a forward PE of 12.50, which, while low, may reflect the market's skepticism about the durability of earnings. The beta of 1.106 means the stock is about 10.6% more volatile than the market, and its max drawdown of -32.73% in the past year shows how quickly sentiment can reverse. Competitive pressures from larger, more diversified peers like UnitedHealth and CVS could intensify, especially if they gain share in Medicaid or exchange markets. Regulatory risks are ever-present, with potential changes to ACA subsidies or Medicaid funding formulas that could compress margins. The recent CMS Medicare Advantage rate increase was a positive, but future rate updates could be less favorable.
The worst-case scenario would involve a combination of renewed medical cost inflation, further ACA membership losses, and unfavorable Medicaid rate adjustments. In this scenario, the stock could retest its 52-week low of $31.63, representing a 52.4% decline from the current price of $66.42. The analyst low target of $56.00 implies a 15.7% downside, but if margins revert to 2025 levels, the stock could fall below that. Given the stock's history of sharp corrections, a drop to the low $30s is plausible if the recovery narrative unravels. Investors could lose more than half their capital in such an adverse scenario.
FAQ
The key risks for Centene are ranked as follows: First, membership attrition, particularly in ACA plans, which represent 28% of membership and are declining, forcing cost cuts. Second, margin sustainability risk: the Q1 2026 gross margin of 21.9% may not hold if medical costs rise or Medicaid rates disappoint. Third, regulatory risk: changes to ACA subsidies or Medicaid funding could significantly impact revenue and profitability. Fourth, financial risk: despite $20.59 billion in cash, the debt-to-equity ratio of 0.94 and cash flow to debt of 0.22 indicate moderate leverage, and trailing ROE is -33.44%. Additionally, the stock's beta of 1.106 and max drawdown of -32.73% show it is volatile and can suffer sharp declines.
Our 12-month forecast for Centene includes three scenarios. The base case (55% probability) targets $70-$75, assuming gross margins stabilize around 21% and revenue grows 5-7%. The bull case (25% probability) targets $85-$90, driven by successful membership stabilization and margin expansion above 22%. The bear case (20% probability) targets $50-$56, reflecting renewed cost inflation and membership losses. The most likely scenario is the base case, with the key assumption that the Q1 2026 margin recovery is sustainable and that ACA membership declines are offset by Medicaid and Medicare growth. Analyst consensus average target is $71.78, aligning with our base case.
Centene appears undervalued on most metrics. The price-to-sales ratio of 0.10 is near historic lows, down from 1.29 in Q4 2022, and the price-to-book ratio of 1.01 means it trades at book value. The forward PE of 12.50 is below the broader market and likely below the managed care sector average. However, the trailing PE is negative due to 2025 losses, and the EV/EBITDA is distorted. The market is pricing in a moderate earnings recovery, but not a full return to prior profitability. If the company can sustain its Q1 2026 gross margin of 21.9% and grow earnings, the stock could re-rate higher. Conversely, if margins falter, the low valuation could persist or worsen, making it a value trap.
Centene is a good buy for value-oriented investors who believe the margin recovery is sustainable, but it carries significant risks. The stock trades at a forward PE of 12.50 and a price-to-sales ratio of 0.10, which are deep-value levels, and analysts have a 'buy' consensus with an average target of $71.78, implying 8.1% upside. However, the company is losing ACA members, which forced staff buyouts, and trailing profitability is negative with a net margin of -3.43%. The biggest downside risk is a retest of the 52-week low of $31.63, representing a 52% decline. For risk-tolerant investors with a long horizon, the risk/reward is favorable, but conservative investors may want to wait for more evidence of sustainable margin improvement.
Centene is more suitable for a medium-to-long-term investment horizon of at least 2-3 years, given its turnaround nature and the need for sustained margin recovery. The stock does not pay a dividend, so returns depend entirely on capital appreciation. Its beta of 1.106 and history of sharp drawdowns (max -32.73%) make it volatile, so short-term trading carries high risk. The company's earnings visibility is improving but still uncertain due to policy and membership dynamics. Long-term investors can benefit from the deep value valuation and potential re-rating if management executes on cost cuts and margin improvement. A minimum holding period of 2 years is suggested to allow the recovery story to play out.
